Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022Business Wire • 11/03/22
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric PatientsBusiness Wire • 11/02/22
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver DiseaseBusiness Wire • 11/01/22
With A Breakout On The Line, Gilead Sciences Reports Massive Cancer Drug SalesInvestors Business Daily • 10/27/22
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of ComorbiditiesBusiness Wire • 10/24/22